Skip to contentL
Lexicon Pharmaceuticals, Inc.
L
LXRXLexicon Pharmaceuticals, Inc. Q1 2024 · 10-Q
Revenue$1.09M$1.09M— vs Q1 2023 Net Income-$48.40M-$48.40MN/M vs Q1 2023 EPS Diluted-$0.20-$0.20N/M vs Q1 2023 Operating Income-$45,333,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lexicon Pharmaceuticals, Inc. · CIK 1062822 · Engraved from SEC EDGAR
Free Cash Flowderived-$55,130,000N/M Margins · derivedOperating margin-4147.6%
Net margin-4427.9%
ended Mar 31, 2024 · filed May 2, 2024 · 32 d after period end